Johns Hopkins University Center for Tuberculosis Research, 1551 Jefferson Street, #154, Baltimore, MD 21287, USA.
Future Microbiol. 2011 Oct;6(10):1185-98. doi: 10.2217/fmb.11.101.
Until 2004, the skin disease known as Buruli ulcer, caused by Mycobacterium ulcerans, could only be treated by surgery and skin grafting. Although this worked reasonably well on early lesions typically found in patients in Australia, the strategy was usually impractical on large lesions resulting from diagnostic delay in patients in rural West Africa. Based on promising preclinical studies, treatment trials in West Africa have shown that a combination of rifampin and streptomycin administered daily for 8 weeks can kill M. ulcerans bacilli, arrest the disease, and promote healing without relapse or reduce the extent of surgical excision. Improved treatment options are the focus of research that has increased tremendously since the WHO began its Global Buruli Ulcer Initiative in 1998.
直到 2004 年，由溃疡分枝杆菌引起的皮肤疾病，即众所周知的布鲁里溃疡，只能通过手术和植皮来治疗。虽然这种方法对澳大利亚患者中早期的典型病变效果相当好，但在西非农村地区由于诊断延误导致的大病变时，这种策略通常不切实际。基于有前景的临床前研究，在西非进行的治疗试验表明，利福平与链霉素联合使用，每日一次，连续 8 周，可以杀死溃疡分枝杆菌，阻止疾病发展并促进愈合，而不会复发或减少手术切除的范围。自世卫组织于 1998 年发起全球布鲁里溃疡倡议以来，研究的重点一直是改善治疗选择，相关研究数量大幅增加。
